Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLIMACTERIC, MALE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1992

Middle-aged Danish men's ideas of a male climacteric--and of the female climacteric.

The concept of a male climacteric as a parallel to the female climacteric appeared in both popular and scientific literature before 1940. The present population study describes the ideas regarding a male climacteric reported by a sample of men at the ages of 40, 45 and 51. The proportion who believed in the occurrence of a male climacteric decreased as the men became older, although 30% still believed in the phenomenon at the age of 51. Around a fifth (18%) of the 51-year-old men had felt or still felt that they were climacteric. This feeling was significantly related to the men's concern about a climacteric partner and to the presence of 'hot flushes or sweating' in the men. No relation was found with either the men's hormone levels (serum luteinizing hormone and serum free testosterone), or the myths that often surrounded the midlife crisis. The male climacteric therefore seems to serve as an explanation for various common non-specific complaints.

Adult↗
PubMed1989

The questionable physiologic and epidemiologic basis for a male climacteric syndrome: preliminary results from the Massachusetts Male Aging Study.

This paper examines the physiologic and epidemiologic evidence for a widely discussed syndrome termed either 'mid-life crisis', 'male menopause', 'male climacteric', or increasingly, 'andropause'. The paper is divided into 2 parts: (1) a review of evidence from physiologic studies conducted over the last decade that examine endocrine function in aging males; (2) a description of the salient features of an ongoing multidisciplinary epidemiologic study (the Massachusetts Male Aging Study) of a sample of approximately 1700 men aged 40-69 yr, randomly sampled from the general population. This study is markedly different in size and content from studies conducted to date. Preliminary findings suggest that age per se may be a relatively unimportant contributor to endocrine variability and that anthropometrics and life style phenomena may be at least as important.

Adult↗
PubMed2004

[Male climacteric syndrome (andropause)].

The concept of male climacteric syndrome or andropause was advanced 55 years ago based on the fact that some men aged over 50 would present similar clinical symptoms as menopausal women. Since then, many related concepts have been presented to describe this specific period of time in men's life, and controversies have never ceased on this concept and its implication. To represent this unique phenomenon in a very general manner, such terms as male climacteric syndrome (andropause), late-onset hypogonadism, and partial androgen deficiency in the aging male (PADAM) are extensively used in clinical practice at the present time. But strictly speaking, these terms differ significantly, each representing a specific physiological condition. Out of different objectives, researchers might use some of the concepts to design their experiments or summarize related data. But it is very important for them to clarify real intentions and particular characteristics of selected research objects, so as to choose and use a proper concept.

Adult↗
PubMed2005

[Clinical study of recombinant human growth hormone for male climacteric syndrome].

OBJECTIVE: To evaluate the effect and safety of the recombinant human growth hormone (rhGH) in the treatment of male climacteric syndrome and to investigate the specificity and sensitivity of insulin-like growth factor-1 (IGF-1) and serum total testosterone as the curative effect index. METHODS: Forty patients aged 40-75 with male climacteric syndrome were divided into two groups randomly and injected with rhGH 4 IU (Group A) or 8 IU (Group B). The patients were followed up for about 12 weeks after 12-week treatment and then asked the questions of the assessed index of male climacteric syndrome at the 4th, 8th and 12th week of the treatment and 12 weeks after the treatment. The serum IGF-1, total testosterone (TT) and prostatic specific antigen(PSA) were measured before and after the treatment. The data were analysed by the software of SPSS 12.0 for Windows. RESULTS: The scores of the 4th, 8th and 12th week and the follow-up significantly declined compared with the baseline (P < 0.01), but did not differ significantly between Groups A and B (P > 0.05). After the treatment, serum total testosterone, PSA and prostate volume had no obvious change (P > 0.05), and the IGF-1 level was markedly higher than the baseline and the normal public. No obvious side effect was found during the treatment and follow-up. CONCLUSION: Small dosage of rhGH(4 IU/week) for 12 weeks can effectively treat male climacteric syndrome. The value of IGF-1 was parallel with the treatment effects. Short-time and small-dosage treatment with rhGH is safe and has little side effect.

Andropause↗
PubMed1994

[The male climacteric. A responsibility for dermatologic andrology?].

Sexual impotence is considered to be the main symptom of the male climacteric, corresponding to the female menopause. While the female climacteric is routinely observed and treated by gynecologists, there are no adequate institutions for the treatment of the corresponding male complaints. Like ovarian secretion of estrogens, which declines and thus causes the female climacteric syndrome, the endocrine metabolism of the testes decreases with increasing age. The period of this decrease, however, is far more extended than that of estrogen secretion in women. Several recent studies have yielded evidence that any disease--irrespective of its kind--in the aging man influences the decrease of testosterone levels more markedly than his age. In 1986 a study group in New England inaugurated the "Massachusetts Male Aging Study" in which healthy men in different age groups were tested for hormone levels. The most prominent result of this study was a decrease in mean testosterone levels by 1% and a decrease in the mean free testosterone levels by 1.2% per year of age. The study also allows recommendations for hormone substitution. The decrease in sexual function in the aging male does not correlate with the decrease in testosterone production. In summary, however, there is no doubt that the frequency of sexual dysfunction increases with advancing age, partly because of drug interactions. As there does not seem to be any sound basis for assuming an endocrine basis for the male climacteric, other reasons must probably be sought for the male climacteric or mid-life crisis.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1992

[The male climacteric from the practical viewpoint].

A transient physiologic period similar to that in women leads from full sexuality to senium in the life of men, too. This phase may involve the complex of male climacteric symptoms. The diminished testosterone secretion of the testes as endocrine "primum movens", together with an increased level of the carrier protein (SHBG), results in a reduced androgen supply of the organism, as reflected in a low free andorgenic index. The diagnosis of male climacteric is made on the basis of an enhanced serum LH level. With regard to the differential diagnosis, atherosclerosis, diabetes mellitus, chronic alcoholic liver damage, malignant tumors and prostatic complaints are particularly to be considered. The hormonal treatment consists of low-dose testosterone medication; for the prevention of osteoporosis, however, testosterone preparations may be replaced by anabolic steroids. As for women, the concomitant vegetative phenomena of the climacteric syndrome should be alleviated symptomatically.

Climacteric↗